Conditions: Juvenile Idiopathic Arthritis
Allocation: NON_RANDOMIZED | Intervention model: PARALLEL
Enrollment: 52
Healthy volunteers: no

Brief summary:
This open-label, multicenter study evaluated the pharmacokinetics, pharmacodynamics and safety of SC administered TCZ in participants with pJIA.

Detailed description:

Arms:
arm 1: Participants with body weight less than (\<) 30 kilograms (kg) will be administered 162 milligrams (mg) of TCZ as a SC injection every 3 weeks (Q3W) for 52 weeks. arm 2: Participants with body weight greater than or equal to (\>/=) 30 kg will be administered 162 mg of TCZ as a SC injection every 2 weeks (Q2W) for 52 weeks.

Interventions: intervention 1: Tocilizumab
Intervention descriptions: intervention 1: Participants will receive 162 mg of TCZ as SC injection Q3W or Q2W for 52 weeks

Protocol document: